Mind Medicine (NEO: MMED) has begun the first clinical trials focused on combining MDMA and LSD. The trials, to be conducted at the University Hospital Basel Liechti Lab in Switzerland, will look to measure and evaluate the effects on the body of the drugs when used in combination with one-another.
MindMed is currently working under the hypothesis that when used in combination, positive side effects of the drugs may improve, including positive mood and empathy, while reducing negative emotions that can be associated with that of LSD. The trial will focus on whether MDMA is able to offset some of these known negative side effects of LSD that can occur in therapy or clinical settings.
The study itself will be conducted as a phase 1 double-blind placebo controlled study, which includes a 4-period crossover design. Within, the trials will evaluate the subjective and autonomic effects with a focus on qualitative emotional differences between four separate experiences: a combination of MDMA and LSD, pure LSD, pure MDMA, and finally a placebo.
LSD has found in certain phase 1 studies to demonstrate serotonin receptor stimulation, which has lead to ego dissolution and neuroplasticity, which are believed to have therapeutic effects on those suffering from mental disorders. If the study conducted is proven successful, MindMed intends to undertake studies with treatments combining both MDMA and LSD for several potential mental disorders and indications.
The study is anticipated to take roughly one year.
Mind Medicine last traded at $3.83 on the Neo.
Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.